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Introduction 
The prevalence of chronic obstructive pulmonary disease (COPD) in Switzerland is 
approximately 10%, comparable to other European countries(1, 2). COPD is associated with 
high morbidity, increased mortality and enormous economic costs(1, 4). COPD has therefore 
became a focus of the “QualiCCare” project, initiated by the Swiss Federal Department of 
Home Affairs (FDHA) in 2011 with the aim to improve quality in chronic disease care on a 
national level. The driving force behind “QualiCCare” was the mounting evidence that 
patients with chronic health conditions do not receive recommended care despite existing 
clinical practice guidelines(5). This is a problem in particular for patients with COPD, who 
receive recommended treatment only during 50% of encounters with providers(6-8). 
Studies from various countries have shown that successful COPD care with  improved 
quality of life and reduced use of health care resources is based on appropriate 
pharmacological treatment, planned regular visits, patient education, adequate exacerbation 
management and collaborative, integrated disease management(9, 10,) (11). Guidelines 
address management of stable COPD  as well as exacerbations and give recommendations 
for evidence based care (5, 12). However, variations in treatment and non-adherence to 
recommendations  have a negative impact on the quality of care (8, 13-15). The Institute of 
Medicine (IOM) quality report emphasizes the need for better assessment of care quality by 
measuring performance (16).  
Primary care is pivotal in this respect (17-20) as providers can transfer recommendations  
and implement them into daily practice , prompting quality improvements in care delivery (16, 
21). Therefore, the aim of the present study was to investigate the documentation of COPD 
PMs in primary care practices of the Canton Zurich in Switzerland, based on guideline 
recommendations(5, 12). 
Methods  
The study was part of the improving CARe in Obstructive Lung disease (CAROL) project. 
CAROL is a cluster-randomized controlled trial that aims to assess whether GP and primary 
care team participation in the COPD quality improvement intervention (“QualiCCare”) 
improves adherence to recommended care elements and processes and  which evaluates 
the impact on COPD care. A detailed research protocol has been published 
elsewhere(22).The CAROL study (ClinicalTrials.gov: NCT01921556) was approved by the 
ethics committee of the Kanton Zurich (Ref. KEK-ZH_Nr, 2013-0189).  Protection of privacy 
of both patients and the participating practices was  ensured. 
For this study a multi-site retrospective design was chosen analyzing the medical records of 
14 different primary care practices in the canton of Zurich, with a focus on the two major 
regions “Winterthur” and “Zurich”, which care for both urban and rural populations. 
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Setting and participating practices  
The participating practices were recruited from 30 practices (single and group practices) in 
the canton of Zurich who agreed to participate in the CAROL project. Five practices were 
located in the area of Winterthur. Winterthur is the second largest city in the canton with 
about 105’000 inhabitants. Zurich is the largest city with around 390’000 inhabitants. Its 
agglomeration is home to   around 1.19 million people.  
Nine practices were from the area of Zurich. One of the Zurich practices runs the validated 
“Living well with COPD” (LWWCOPD) program(9) since 2010. The LWWCOPD program is 
based on the Chronic Care Model(23)and can be applied to a variety of chronic illnesses and 
health care settings (24). Key elements of the LWWCOPD program are a practice team with 
defined roles, evidence-based practice  incorporating guideline recommendations, patient 
education and self-management support as well as regular follow up and coordination of 
care(25). 
Patient enrolment  
Each participating GP reported patients with physician diagnosed COPD and regular 
outpatient visits in 2012. The selection criteria  required that patients had a physician 
diagnosed COPD and had seen the GP at least three times in 2012, regardless of the reason 
for the consultation. Patients were excluded if they died before the end of 2012. 
Data collection and analysis 
Data collection comprised a 12-month retrospective medical chart review. Demographic and 
clinical characteristics were assessed.  
We analyzed the documentation of COPD performance status  by searching the medical 
notes for the following relevant measures. 1. Assessment of smoking status with smoking 
cessation advice and smoking cessation intervention; 2. Influenza vaccination; 3. 
Assessment and advice for physical activity; 4. Appropriate pharmacological treatment; 5. 
Instruction of correct inhalation technique; 6. Information about disease; 7. Instruction in 
exacerbation management and availability of a written action plan; 8. Advice or referral to 
pulmonary rehabilitation and 9. Proactive and integrated services indicating collaboration and 
networking with specialists, secondary and hospital tertiary care services as well as with 
other health care deliverers and community resources.  
An independent and trained research assistant reviewed each patients medical records   
using a carefully developed checklist including the above specified performance measures 
(PM).   Several data sources were studied, e.g. entries in the medical records, referral  letters 
and invoice coding to ensure comprehensive data collection.  
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In order to  assess the severity of COPD spirometry results from  the time of  diagnosis and  
follow-up measurements from 2012 were included in the data analysis. The majority (91/115) 
of the medical records were computer based, 24 were paper based.  
Outcome measures 
 For each patient the number of documented performance indicators was calculated. A 
composite score was established and noted.A Score of 1: denoted the documentation of 0-2 
PMs, a Score of 2 the documentation of 3-5 PMs, a Score of 3: the documentation of 6-8 
PMs and a Score of 4:the documentation of all nine PMs. 
These results were compared to the practice running the validated LWWCOPD program 
(practice B).  
Statistical analysis 
Patient characteristics and documented PMs are presented as means (range) and 
percentages for the total population and stratified according to the regions Zurich and 
Winterthur as well as the practice running the COPD program (practice B). Group 
comparisons of patient characteristics and PMs were performed by unpaired t-tests and chi-
squared statistics as appropriate. Fisher exact test was used for small sample sizes (n<5). 
Results 
Practices characteristics  
Data from 14 primary care practices (7 single, 7 group practices) were evaluated. Five of the 
practices were located in the region of “Winterthur” and nine in the “Zurich” region. Data from 
115 patients (37 in Winterthur, 78 in Zurich) were available; the majority of the patient data 
were collected in group practices (83%) and from computer based (79%) medical records 
(table 1). The group practice in Zurich running the “Living well with LWWCOPD program(9) 
(practice B) contributed 20 computer based medical records to this study (table 1).  
Patient characteristics  
Data from 115 patients (57% male) with a mean age of 68 years (range 44-93) were 
analyzed (table 2). Most baseline characteristics of the patients showed no significant 
difference between the practices without a COPD program (Total-B) and the practice in 
Zurich with the COPD program (B). Patients from practice B  were more likely to be active 
smokers, had   received a diagnosis of COPD more recently and were subjected to 
significantly more spirometries in 2012.  
In general, no big difference in patient characteristics existed between the COPD patients 
from the rural (Winterthur) and the urban (Zurich) population in our study. COPD patients 
from Winterthur had been diagnosed with COPD for a significantly shorter amount of time 
 5  
 
than those in Zurich (table 2). The burden of comorbidities was high with documentation of 
one or more comorbidities in 73% of  patients. The most frequently documented 
comorbidities were hypertension (57%), followed by coronary heart disease (28%), 
depression (23%), diabetes (15%) and heart failure (9%). However, heart failure and 
diabetes were not documented in the twenty patients from practice B.  
Spirometric confirmation of COPD was documented in 83%, either at the time of diagnosis or 
during follow up in 2012. The year of COPD diagnosis was documented in 94 of the 115 
patients (82%) and ranged between 1997 and 2012; on average COPD diagnosis was 
established 5.28 years before the current data collection.  
At the time of diagnosis, GOLD classification (12) was documented in 80 patients (70%). Of 
these 11% were classified as GOLD I, 64% as GOLD II , 21% as GOLD III and 4% as GOLD 
IV. GOLD classification in 2012 was documented in 87 of the 115 patients (76%) with 8% of 
COPD patients classified as GOLD I, 51% as GOLD II, 23% as GOLD III and 9% as GOLD 
IV.  
Documentation of at least one of the main clinical symptoms of COPD (cough, sputum, 
and/or dyspnea) was found in 83% of the medical records. Dyspnea was the most frequently 
documented symptom in 68%, followed by cough in 54% and sputum production in 35% of 
patients.  
In half (53%) of the patient records exacerbations could be tracked with an average of 1.4 
exacerbations/year and ≥2 exacerbations within 12 months in 16% of patients. On average 
1.24 hospitalizations per year because of COPD were necessary (table 2).  
Documentation of performance measures   
Table 3 and figure 1 show the documentation of non-pharmacological PMs. 
Smoking status and smoking cessation counseling:  
In total smoking status was documented in 95% of the patients. Fifty patients (46%) were 
current smokers . Pack years (py) were documented in 77% with an average of 56 py (range: 
22-150 pack years). In 74% of the current smokers smoking cessation advice was given and 
a stop smoking program  initiated in 52%. 70% of the current smokers were documented as 
being motivated to cease smoking, 34% were not.  
Practices without a COPD program (Total–B =A) vs. the practice with LWWCOPD program 
(B)The percentage of documented smoking cessation advice offered in active smokers was 
65% in practices A, and 100% in practice B. A smoking cessation program was initiated in 
38% of the smokers in practices A and in 92% of smokers in practice B, a significantly higher 
percentage (p<0.01). 
Influenza vaccination:  
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Overall, half of the patients  received an influenza vaccination/recommendation in 2012 
without any statistical difference between the regions or between A (49%) and B (45%). 
Physical activity and pulmonary rehabilitation:  
In 60% of all patient records assessment of physical activity and in 53% motivation and 
advice for physical activity was detailed.  
Practices without COPD program (A) vs. practice with LWWCOPD program (B) 
In practices A assessment of physical activity was documented in 52% of patients compared 
to 95% of patients in B. All patients in practice B were given advice regarding  pulmonary 
rehabilitation compared to eleven (12%) in A. In 85% of patients in practice B a referral to a 
pulmonary rehabilitation program was traceable compared to 12% of patients in the A 
practices. These differences were highly significant (p<0.01). 
Information about COPD, information about therapy and instruction in correct 
inhalation technique: 
These three quality indicators  were documented in 45% to 48% of patients in practices A 
compared to 95% in practice B  (the practice running the LWWCOPD  program), denoting a 
significant difference  (p<0.01). 
Exacerbation management and written action plan:  
Instructions regarding exacerbation management  were traced in only 24% of patients 
records and an action plan recorded in only 16% of patients.  
Practices without COPD program (A) vs. practice with LWWCOPD program (B) 
Analysis of patients charts from A showed  scant  documentation of instructions regarding 
exacerbation management (8%) or the existence of an action plan (2%), with no regional 
difference between Zurich and  Winterthur. Instructions for exacerbation management were 
documented in all patient notes from practice B and 80% additionally had a clear  action plan 
recorded (p<0.01).  
Proactive follow up and integrated services for patient care:  
For 60% of all COPD patients integrated care was documented. Contact with pneumologists 
was registered in 57%,  with hospitals in 39%, physiotherapists in 32% and community 
support services in 15%. In about half of all medical records, a proactive follow up of COPD 
patients was documented.  
Practices without COPD program (A) vs. practice with LWWCOPD program (B) 
In practices A integrated care was documented in 53% compared to 95% of patients in 
practice B (p<0.01). Collaboration with a specialist was documented in 40% of COPD 
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patients from A compared to 95% of patients from B. Proactive care and regular follow up 
was significantly more frequent in B (95%) compared to A (42%) (p<0.01).  
Pharmacological treatment:  
Table 4 summarizes the COPD treatment regimes prescribed. The mean number of 
documented COPD medications was 2.09 (range: 0-6 drugs) without any significant 
difference between settings A and B or between the regions of Zurich and Winterthur. 
80 of 115 patients (70%)  were treated with inhaled corticosteroids (ICS), 70 of 80 patients 
(61%) in combination with a long-acting beta2-agonist (LABA). With respect to the disease 
severity recorded (32% GOLD III or GOLD IV documented in 2012) and  the frequency of 
exacerbations (16%) this reflects overtreatment. Patients with severe COPD and patients 
with frequent exacerbations received adequate treatment with ICS (86% and 81% 
respectively) . 
Eighty-one out of 115 (70%) patients were prescribed a long-acting antimuscarine antagonist 
(LAMA). Long-acting beta2-agonist (LABA) treatment was documented in 22%.  
Short acting beta2-agonists (SABA) were prescribed in 36% of the COPD patients, whereas 
none of the patients inhaled a short acting antimuscarine antagonist (SAMA). Only 6 out of 
115 patients (5%) were prescribed a combination of a short-acting beta2-agonist and a short-
acting antimuscarine antagonist (SABA/SAMA). In Winterthur significantly fewer patients 
were given  an ICS/LABA combination therapy (43%) compared to the Zurich practices. This 
was true both for those practices with and those without a COPD program (70% versus 69% 
respectively). In Winterthur significantly more patients were prescribed LAMA (84%), 
compared to the Zurich practices without the LWWCOPD  program (59%). LAMA treatment 
was prescribed to 80% of patients in the practice implementing the LWWCOPD  program 
Treatment with LABA was documented in 32% of patients in Winterthur, and in 16% and 
20% of the patients in the Zurich practices with and without the LWWCOPD program, 
showing no statistical difference (table 4). 
Composite score of documented performance measures:  
Overall all practices had low scores of 1 or 2 (in 60% of patients). A score of 1 (0-2 PMs 
documented) was found in 23%, a score of 2 (3-5 PMs) in 37% of patients. A score of 3 (6-8 
PMs) could be established in 34% and the maxium score of 4 (with all nine PMs 
documented) in only 7% of the 115 medical records.  
Comparison with B showed that significantly higher scores of 3-4 in 95% of patients  were 
achieved compared to 29% in A. 
Discussion  
Main findings 
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This is the first evaluation of the documentation of COPD PMs in a primary care setting in 
Switzerland. Our data demonstrate a documentation gap in relation to recommended care 
and a wide variation between practices regarding documentation of COPD PMs. A 
significantly better documentation of COPD PMs was achieved with the implementation of a 
validated COPD program(26).  
Strength and limitations 
COPD represents an important condition in which improvement of care would in all likelihood 
have a high impact.. A strength of our study was that the assessed measures were validated 
to demonstrate effects on clinically important patient outcomes. We did not rely on 
questionnaires sent to the GPs, but  had  patient records and data gathering systems 
systematically reviewed by an independent research assistant , thus ensuring 
comprehensive data  collection. 
Limitations of this study include the low sample size, documentation bias and generalisability 
of the results. The participation of practices and GPs that were part of the CAROL study, a 
prospective RCT,  represent a selected and probably more motivated GP population. 
However, the latter would likely have biased the data toward an underestimation of the 
documentation gap. Small samples are more prone to the play of chance which means that 
the significant effects which are observed in this study may  be skewed. In the practice 
implementing a COPD program a   chest physician and a respiratory physiotherapist  were 
part of  the team and  oversaw the LWWCOPD program. Referrals and coordination of care 
were therefore more easily accomplished. This redesign of care using  an inhouse care team 
approach is not common in Swiss primary care. In addition, the quality of documentation was 
assessed in the canton of Zurich and cannot be generalized to Switzerland as a whole or 
other countries and health care systems. 
Finally, yet importantly, missing documentation is not synonymous with  poor performance. 
Some PMs may have been implemented but not documented by the GPs. It is also likely that 
in patients referred to specialists the PMs were documented but not explicitely mentioned in 
reports sent to the GPs. It is difficult  to conclude from our data how wide the gap between 
current and ideal COPD practice is and how this gap varies across different organizations. 
Interpretation of findings in relation to previously published work 
Two thirds of patients in our study received smoking cessation advice, but only around half  
received recommendations regarding influenza vaccination.  
Smoking cessation is the only intervention that slows the rate of lung function decline and 
improves survival in COPD patients(27, 28). The documented counselling rate in the present 
study is much better than the 50% reported from former Swiss primary care data and is more 
in line with international benchmarks(8, 13).  
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Influenza vaccination prevents acute exacerbations of COPD and reduces the  rate  of 
hospitalization by about 40%-50%(29). The low documented influenza vaccination 
percentage (only half of the COPD patients) therefore reflects a substantial deficit  with 
negative implications for patients and the health care system. This could be changed by 
implementing reminder and recall interventions, as shown in data from other countries (30). 
Our data also indicate that only a minority of COPD patients in primary care are offered 
pulmonary rehabilitation advice or a referral for pulmonary rehabilitation, in line with data 
from other countries(13). The remarkably  low documentation of self-management support 
and exacerbation-management or instruction with a written action plan is striking. Pulmonary 
rehabilitation and self-management education are effective ways of lessening the impact of 
COPD burden on patients and the health system by preventing exacerbations and hospital 
admissions as well as readmissions (9, 31). In half of the patient records documentation of 
exacerbations  wasfound. The percentage of frequent exacerbations  (16% of patients) and 
an average of 1.24 hospitalizations per year because of COPD exacerbations suggest that 
the awareness for these as the main drivers of morbidity and cost has to be increased and 
that rehabilitation and self-management education need to be proclaimed as effective 
preventive actions, in analogy to programs established for  heart disease(32). A recently 
published report by Australian GPs identified an awareness barrier, insufficient  knowledge of 
how to refer for pulmonary rehabilitation, anticipated access difficulties for patients and cost 
benefit issues as major problems (33). 
Spirometric confirmation of COPD with a remarkably high documentation of GOLD grading 
according to guidelines(5) revealed that the majority of evaluated COPD patients have mild 
to moderate COPD. A lasting hot topic in COPD management is pharmacological 
overtreatment with ICS in patients with mild to moderate disease, as confirmed in our 
study(5, 12). While overtreatment with ICS was common , undertreatment in those with 
severe disease or frequent exacerbations was less frequent.  
With respect to effective treatment a correct inhalation technique is of central importance and 
depends on the correct use of the inhalation device. Instruction of inhalation technique was 
performed significantly more often in the practice with the COPD program, where almost all 
of the patients were trained compared to less than half of the patients from the other 
practices. Last but not least a change from reactive to more proactive and integrative care is 
necessary to achieve better outcomes in COPD (10, 18, 34). A significantly higher 
percentage of proactive follow up and integrated care in the practice implementing the COPD 
program was found,  which can be explained by the integration of a chest physician, 
respiratory physiotherapist and a trained practice assistant into the team, facilitating  
referrals, information transfer and care coordination.  
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Taking together all our data, we found that one third of the patients from general health care 
practices received documented high quality care compared to 95% of the patients enrolled in 
the LWWCOPD program. These rather impressive differences warrant deeper reflection and 
discussion. 
The LWWCOPD program(9) is based on the Chronic Care Model (CCM)(23). The CCM 
identifies the essential elements of a health care system that encourages high-quality chronic 
disease care. These elements are part of a health system that redesigns care according to a 
care team approach. It uses clinical information systems, supports self-management, and 
facilitates decision support. The focus lies  on forming productive interactions between 
informed patients who take an active part in their care and providers with resources and 
expertise. The practice with the COPD program used some of these elements to improve 
chronic care delivery. A COPD care team ( lung physician, respiratory physiotherapist and 
trained practice assistants) dedicated to guideline based, proactive,coordinated care, 
supported  self-management, offered  regular follow up calls to patients and ensured an 
information transfer between the health care deliverers and the patient. 
Implications for practice, policy and research 
21st century practices should incorporate evidence based processes of care. 
It is not enough to create guidelines but recommendations have to be incorporated into  daily 
practice . PMs are a postulated tool  to help improve health-care quality(21). In the United 
Kingdom, the National Institute for Health and Clinical Excellence (NICE) guideline 
implementation strategies use financial and regulatory incentives, including pay-for-
performance(35). However, concerns in linking financial incentives to performance exist. It is 
argued that performance measures are poor predictors of quality and that rewarding quality 
improvement actions could make more sense than spending resources on measures(36). 
PMs alone will not improve care unless the results of those measures are linked to efforts to 
diagnose and eliminate core causes of poor quality and point the way to integrating and 
coordinating care(37). Some of the most established causes for poor quality are a lack of 
resources  to transform practices and  implement quality improving health care delivery 
concepts like the CCM and the patient centered medical home (PCMH)(23, 34).  
A central cornerstone for better quality will be value-based reimbursement, rewarding those 
who contribute to high-quality, cost-effective care across the continuum, regardless of 
specialty or venue.  
Conclusion  
Identifying and bridging performance gaps is central to health care quality.COPD represents 
an important target condition in which to implement measures to improve care.  
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Figure 1: legend 
Comparison of documented COPD performance measures between primary 
care practices without a COPD program and the practice running the “Living 
well with COPD” program 
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Practices 
characteristics by 
regions 
Total 
(n=14) 
Total – 
practice 
with 
COPD 
program 
(B) 
(n=13) 
Winterthur 
(n=5) 
Zurich – 
B (n=8) 
Zurich practice 
with COPD 
program (B) 
(n=1) 
No. of patients in 
single practices, n 
(%) 
20 (17) 20 (21) 10 (27) 10 (17) 0 (0) 
No. of patients in 
group practices, n 
(%) 
95 (83) 75 (79) 27 (73) 48 (83) 20 (100) 
Total No. of 
patients, n (%) 
115(100) 95 (83) 37 (32) 58 (50) 20 (17) 
No. of computer 
based medical 
records, n (%) 
91 (79) 71 (75) 31 (84) 40 (69) 20 (100) 
No. of paper based 
medical records, n 
(%) 
24 (21) 24 (25) 6 (16) 18 (31) 0 (0) 
 
  
Table 1: Characteristics of the participating practices 
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Patient characteristics 
 
Due to missing data n is in several 
categories lower than indicated here. 
The percentages correspond to the 
effective n. 
Total 
(n=115) 
Total – B 
(n=95) 
Winterthur 
(n=37) 
Zurich – B 
(n=58) 
B (n=20) 
Age, years, mean (range: Min 44y, 
Max 93 y) 
 68.25 68.74 64.25 72.25 68.70
Male, n (%) 66 (57) 58 (61) 21 (57) 37 (64) 8 (40)
BMI (kg/m2), (range: Min 17kg/m2, 
Max 43kg/m2) 
27 27 27 27 26
Current smokers, n (%) 50 (46) 37 (41) 17 (52) 20 (35) 13 (68)*
Pack Years, mean (range: 22-
150years) 
56 57 50 62 47
≥ 1Comorbidities●, n (%) 84 (73) 73 (76) 28 (76) 45 (78) 11 (55)
Diabetes 17 (15) 17 (18) 6 (16) 11 (19) 0 (0)
Hypertension 65 (57) 57 (60) 21 (57) 36 (62) 8 (40)
Coronary artery disease 32 (28) 28 (29) 7 (19) 21 (36) 4 (20)
Heart failure 10 (9) 10 (11) 3 (8) 7 (12) 0(0)
Depression 27 (23) 23 (24) 10 (27) 13 (22) 4 (20)
Spirometry at COPD onset, n (%) 72 (59) 61 (57) 23 (62) 38 (66) 11 (63)
GOLD at COPD onset, n (%) 80 (70) 68 (72) 24 (65) 44 (76) 12 (60)
GOLD I at COPD onset, n (%) 9 (11) 9 (13) 3 (13) 6 (14) 0 (0)
GOLD II at COPD onset, n (%) 51 (64) 41 (60) 14 (58) 27 (61) 10 (83)
GOLD III at COPD onset, n (%) 17 (21) 16 (24) 7 (29) 9 (20) 1 (8)
GOLD IV at COPD onset, n (%) 3 (4) 2 (3) 0 (0) 2 (5) 1 (5)
Spirometry in 2012, n (%) 67 (58) 48 (51) 19 (51) 29 (50) 19 (95)**
GOLD in 2012, n (%) 87 (76) 68 (72) 24 (65) 44 (76) 19 (95)
GOLD I in 2012, n (%) 7 (8) 6 (9) 3 (13) 3 (7) 1 (5)
GOLD II in 2012, n (%) 44 (51) 34 (50) 12 (50) 22 (50) 10 (53)
GOLD III in 2012, n (%) 28 (23) 23 (34) 9 (38) 14 (32) 5 (26)
GOLD IV in 2012, n (%) 8 (9) 5 (7) 0 (0) 5 (11) 3 (16)
Years since COPD onset, mean range 
(Min 1y, Max 16y) 
5.28 5.69 4.32 6.54# 2.69**
Cough, n (%) 62 (54) 54 (57) 18 (49) 36 (62) 8 (40)
Sputum production, n (%) 40 (35) 32 (34) 9 (24) 23 (40) 8 (40)
Dyspnoe, n (%) 78 (68) 62 (65) 22 (59) 40 (70) 16 (80)
Severity of dyspnea (MRC scale): 0-2, n 
(%) 
22 (76) 8 (67) 3 (75) 5 (63) 14 (82)
Severity of dyspnea (MRC scale): >2, n 
(%) 
7 (24) 4 (33) 1 (25) 3 (38) 3(15)
Exacerbations/year, mean (range: 0-4 
Exacerbations) 
1.39 1.42 1.28 1.50 1.27
≥2 Exacerbations/year, n (%) 16 (16) 13 (26) 4 (22) 9 (28) 3 (27)
Hospitalisations/year, mean (range: 0 
-3 Hospitalisations) 
1.24 1.25 1.00 1.33 1.20
Table 2: Patient characteristics (% depend on the amount (n) of documented characteristics)
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*p=0.030; **p<0.01 compared to (Total-B); #p=0.012 compared to Winterthur 
●The comorbidities heart failure and diabetes were not documented in the twenty patients from practice B, therefore 
statistical comparison can’t be done between B and the other practices. 
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Documentation of 
performance measures 
Total 
(n=115) 
Total – 
B (n=95) 
Winterthur 
(n=37) 
Zurich - 
B (n=58) 
B  
(n=20) 
Assessment of smoking status, 
n (%) 
109 (95) 90 (95) 33 (89) 57 (98) 19 (95)
Smoking cessation advice, n 
(%) 
(n=50 active smokers) 
37 (74) 24 (65) 12 (71) 12 (60) 13 
(100)*
Smoking cessation 
intervention, n (%) (n=50 
active smokers) 
26 (52) 14 (38) 9 (53) 5 (25) 12 (92) 
**
Annual influenza vaccination, 
n (%) 
56 (49) 47 (49) 16 (43) 31 (53) 9 (45)
Assessment of physical 
activity, n (%) 
69 (60) 50 (52) 20 (54) 30 (52) 19 (95) 
**
Advice for physical activity, n 
(%) 
61 (53) 42 (44) 17 (46) 25 (43) 19 (95) 
**
Instruction in correct 
inhalation technique, n (%) 
65 (57) 46 (48) 13 (35) 33 (57)# 19 (95) 
** 
Information about the 
therapy, n (%) 
62 (54) 43 (45) 12 (32) 31 (53)# 19 (95) 
**
Information about disease, n 
(%) 
64 (56) 45 (47) 15 (41) 30 (51) 19 (95)
Instruction in exacerbation 
management with a written 
action plan, n (%) 
28 (24) 8 (8) 3 (8) 5 (9) 20 
(100) 
**
Use of a written action plan, n 
(%) 
18 (16) 2 (2) 1 (3) 1 (2) 16 (80) 
**
Advice of pulmonary 
rehabilitation, n (%) 
31 (27) 11 (12) 4 (11) 7 (12) 20 
(100) 
**
Referral to a pulmonary 
rehabilitation, n (%) 
28 (24) 11 (12) 5 (14) 6 (10) 17 (85) 
**
Integrated and coordinated 
care, n (%) 
69 (60) 50 (53) 16 (43) 34 (59) 19 (95) 
**
Proactive care, n (%) 59 (51) 40 (42) 12 (32) 28 (48) 19 (95) 
**
*p=0.012; **p<0.01 compared to Total-B; #p<0.05 compared to Winterthur  
 
  
Table 3: Documentation of non-pharmacological measures (% depend on the amount 
(n) of documented characteristics) 
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Drug Total  
(n = 115) 
Total – B 
 (n =95) 
Winterthur 
(n = 37) 
Zurich – B  
(n = 58) 
B 
(n = 20) 
ICS/LABA, n (%) 70 (61) 56 (59) 16 (43) 40 (69)* 14 (70) 
ICS, n (%) 10 (9) 9 (9) 4 (11) 5 (9) 1 (5) 
LAMA, n (%) 81 (70) 65 (68) 31 (84) 34 (59)** 16 (80) 
LABA, n (%) 25 (22) 21 (22) 12 (32) 9 (16) 4 (20) 
SABA, n (%) 41 (36) 31 (33) 16 (43) 15 (26) 10 (50) 
SABA/SAMA, n 
(%) 
6 (5) 6 (6) 0 (0) 6 (10) 0 (0) 
*p=0.013; **p=0.010 compared to Winterthur 
Abbreviations: 
LABA = Long-acting beta2-agonist; ICS = Inhaled corticosteroids 
ICS/LABA = Combination of a long-acting beta2-agonist and an inhaled corticosteroid in a 
single inhaler; LAMA = Long-acting antimuscarine antagonist; SABA = Short-acting beta2-
agonist  
SAMA = Short-acting antimuscarine antagonist; SABA/SAMA = Combination of a short-
acting beta2-agonist and a short-acting antimuscarine antagonist in a single inhaler 
 
Table 4: Pharmalogical treatment (% depend on the amount (n) of documented characteristics) 
